New Prior Authorization Proposals: Implications for Prescription Drug Access
Why It Matters
The changes could lower administrative burdens, accelerate patient access to medicines, and create transparent data that reshapes insurer‑provider dynamics.
Key Takeaways
- •CMS proposes extending prior‑auth time limits to prescription drugs.
- •New rule aims to cut administrative costs and speed patient treatment.
- •Electronic prior authorizations and APIs are mandated to replace fax.
- •AI tools could streamline reviews but may raise system costs.
- •Transparency metrics will require payers to publicly report PA data.
Summary
The podcast discusses CMS’s latest proposal to extend prior‑authorization deadlines to prescription drugs, building on a 2024 rule that applied only to surgeries and services.
The rule would set a one‑week response window for standard requests and three days for expedited ones, mirroring existing timelines for Medicare Advantage and Medicaid. Blue Cross Blue Shield recently reported an 11% drop in prior‑auth volume, and the Health Affairs Insider report estimates prior‑auth costs at $35 billion annually.
Guest Michael Gerber emphasizes that reducing paperwork saves practices money and speeds patient care, while also warning that AI‑driven automation could create a “payer‑bot vs. provider‑bot” arms race and increase transaction costs, as highlighted by a recent Peterson Institute study.
If finalized, the proposal mandates electronic prior authorizations via APIs and requires public reporting of approval, denial, and appeal metrics, potentially reshaping insurer workflows, prompting state‑level regulatory patches, and offering new data for research on cost and outcomes.
Comments
Want to join the conversation?
Loading comments...